Prospective Post-marketing Surveillance of Sodium Valproate (SELENICA-R) in migraine patients

Prospective Post-marketing Surveillance of Sodium Valproate (SELENICA-R) in migraine patients - Prospective Post-marketing Surveillance of Sodium Valproate (SELENICA-R) in migraine patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007036

Enrollment

1000

Registered

2012-01-15

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who fulfills all the following conditions. Age is unquestioned. 1) The patient whose daily activity is inhibited although some acute treatment for migraine attack. 2) The patient who has 2 or more migraine attacks per month. 3) The patient who has not been exposed Sodium Valproate for past one year. 4) The patient whose situation of his/her migraine headache can be clearly described at least four weeks before the start of medication. 5) The patient who has not be prescribed any prophylaxis medication during three-month before the start of medication, or has not changed the prophylaxis medication.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1) Alteration of migraine days and attack frequency 2)Improvement factor	—

Countries

Japan

Contacts

Public ContactTakao Takeshima

Tominaga Hospital Department of Neurology, Headache Center

06-6568-1601

Outcome results